Literature DB >> 35490454

Drug monitoring in systemic lupus erythematosus.

Michelle Petri1.   

Abstract

Therapeutic drug monitoring (TDM) is not yet accepted by systemic lupus erythematosus (SLE) treatment guidelines. Studies in SLE, however, have proven benefit in three areas: identification of non-adherence or poor adherence; targets for clinical benefit; and ranges of toxicity. This review covers the data on three medications commonly used for SLE, drawing on studies from both the SLE and non-SLE literature.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Azathioprine; Hydroxychloroquine; Mycophenolate; Systemic lupus erythematosus; Therapeutic drug monitoring

Mesh：

Substances：

Year:  2022        PMID： 35490454      PMCID： PMC9167773          DOI： 10.1016/j.coph.2022.102225

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN： 1471-4892            Impact factor:   4.768


  75 in total

1.  Pharmacokinetics of mycophenolic acid in severe lupus nephritis.

Authors:  Paungpaga Lertdumrongluk; Poorichaya Somparn; Wonngarm Kittanamongkolchai; Opas Traitanon; Somratai Vadcharavivad; Yingyos Avihingsanon
Journal:  Kidney Int       Date:  2010-06-09       Impact factor: 10.612

Review 2.  Cost-effectiveness of therapeutic drug monitoring: a systematic review.

Authors:  D J Touw; C Neef; A H Thomson; A A Vinks
Journal:  Ther Drug Monit       Date:  2005-02       Impact factor: 3.681

Review 3.  Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients.

Authors:  Michelle Petri
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

4.  Comparison of MMF efficacy and safety in paediatric vs. adult renal transplantation: subgroup analysis of the randomised, multicentre FDCC trial.

Authors:  Britta Höcker; Teun van Gelder; Juan Martin-Govantes; Paula Machado; Helio Tedesco; Jacek Rubik; Maud Dehennault; Carmen Garcia Meseguer; Burkhard Tönshoff
Journal:  Nephrol Dial Transplant       Date:  2010-07-28       Impact factor: 5.992

5.  Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus.

Authors:  Catherine M T Sherwin; Anna Carmela P Sagcal-Gironella; Tsuyoshi Fukuda; Hermine I Brunner; Alexander A Vinks
Journal:  Br J Clin Pharmacol       Date:  2012-05       Impact factor: 4.335

6.  Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus.

Authors:  M Jallouli; L Galicier; N Zahr; O Aumaître; C Francès; V Le Guern; F Lioté; A Smail; N Limal; L Perard; H Desmurs-Clavel; D Le Thi Huong; B Asli; J-E Kahn; J Pourrat; L Sailler; F Ackermann; T Papo; K Sacré; O Fain; J Stirnemann; P Cacoub; G Leroux; J Cohen-Bittan; J Sellam; X Mariette; B Blanchet; J S Hulot; Z Amoura; J C Piette; N Costedoat-Chalumeau
Journal:  Arthritis Rheumatol       Date:  2015-05       Impact factor: 10.995

7.  Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients.

Authors:  Jaime Calvo-Alén; Sergio M A Toloza; Mónica Fernández; Holly M Bastian; Barri J Fessler; Jeffrey M Roseman; Gerald McGwin; Luis M Vilá; John D Reveille; Graciela S Alarcón
Journal:  Arthritis Rheum       Date:  2005-07

8.  Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis.

Authors:  Mark T Osterman; Rabi Kundu; Gary R Lichtenstein; James D Lewis
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

9.  Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004.

Authors:  Michael M Ward
Journal:  J Rheumatol       Date:  2009-01       Impact factor: 4.666

10.  Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study.

Authors:  Sarah Djabarouti; Dominique Breilh; Pierre Duffau; Estibaliz Lazaro; Carine Greib; Olivier Caubet; Marie-Claude Saux; Jean-Luc Pellegrin; Jean-François Viallard
Journal:  Arthritis Res Ther       Date:  2010-12-22       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.